{
    "2019-05-02": [
        [
            {
                "time": "2019-05-02",
                "original_text": "After Hours Most Active for May 2, 2019: PFE, CHK, XOM, ESV, CSTM, SRE",
                "features": {
                    "keywords": [
                        "PFE",
                        "active",
                        "after hours"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "energy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Pfizer Stock Rebounds Under Cloud of Negative Charts",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "rebounds",
                        "negative charts"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Drugmakersâ€™ lobbying spending at 10-year high as Washington targets soaring prices",
                "features": {
                    "keywords": [
                        "lobbying",
                        "spending",
                        "soaring prices"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1",
                "features": {
                    "keywords": [
                        "Exelixis",
                        "earnings",
                        "beat estimates"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "beats",
                        "Shingrix"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Pfizer Raised Its Fiscal 2019 EPS Guidance",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "EPS guidance",
                        "raised"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Health Care Sector Update for 05/02/2019: ABIO, CI, TFX, JNJ, PFE, ABT, MRK, AMGN",
                "features": {
                    "keywords": [
                        "health care",
                        "sector update"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "Pfizer Reiterated Its Fiscal 2019 Revenue Guidance",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "revenue guidance",
                        "reiterated"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-02",
                "original_text": "What Are Analysts Recommending for PFE after Q1 Results?",
                "features": {
                    "keywords": [
                        "analysts",
                        "recommendations",
                        "Q1 results"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}